CYBN
Price
$5.82
Change
-$0.04 (-0.68%)
Updated
Sep 26, 03:38 PM (EDT)
Capitalization
152.84M
RXRX
Price
$4.63
Change
-$0.25 (-5.12%)
Updated
Sep 25 closing price
Capitalization
2.02B
40 days until earnings call
Interact to see
Advertisement

CYBN vs RXRX

Header iconCYBN vs RXRX Comparison
Open Charts CYBN vs RXRXBanner chart's image
Cybin
Price$5.82
Change-$0.04 (-0.68%)
Volume$500
Capitalization152.84M
Recursion Pharmaceuticals
Price$4.63
Change-$0.25 (-5.12%)
Volume$47.21M
Capitalization2.02B
CYBN vs RXRX Comparison Chart in %
Loading...
CYBN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CYBN vs. RXRX commentary
Sep 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYBN is a Buy and RXRX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 26, 2025
Stock price -- (CYBN: $5.86 vs. RXRX: $4.63)
Brand notoriety: CYBN and RXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYBN: 193% vs. RXRX: 221%
Market capitalization -- CYBN: $152.84M vs. RXRX: $2.02B
CYBN [@Biotechnology] is valued at $152.84M. RXRX’s [@Biotechnology] market capitalization is $2.02B. The market cap for tickers in the [@Biotechnology] industry ranges from $97.91B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYBN’s FA Score shows that 1 FA rating(s) are green whileRXRX’s FA Score has 1 green FA rating(s).

  • CYBN’s FA Score: 1 green, 4 red.
  • RXRX’s FA Score: 1 green, 4 red.
According to our system of comparison, RXRX is a better buy in the long-term than CYBN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYBN’s TA Score shows that 5 TA indicator(s) are bullish while RXRX’s TA Score has 4 bullish TA indicator(s).

  • CYBN’s TA Score: 5 bullish, 4 bearish.
  • RXRX’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, both CYBN and RXRX are a good buy in the short-term.

Price Growth

CYBN (@Biotechnology) experienced а -2.33% price change this week, while RXRX (@Biotechnology) price change was -6.09% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.59%. For the same industry, the average monthly price growth was +8.82%, and the average quarterly price growth was +54.45%.

Reported Earning Dates

RXRX is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+3.59% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RXRX($2.02B) has a higher market cap than CYBN($153M). RXRX YTD gains are higher at: -31.435 vs. CYBN (-33.560). CYBN has higher annual earnings (EBITDA): -152.51M vs. RXRX (-583.64M). RXRX has more cash in the bank: 525M vs. CYBN (119M). CYBN has less debt than RXRX: CYBN (44.5M) vs RXRX (88.1M). RXRX has higher revenues than CYBN: RXRX (64.5M) vs CYBN (0).
CYBNRXRXCYBN / RXRX
Capitalization153M2.02B8%
EBITDA-152.51M-583.64M26%
Gain YTD-33.560-31.435107%
P/E RatioN/AN/A-
Revenue064.5M-
Total Cash119M525M23%
Total Debt44.5M88.1M51%
FUNDAMENTALS RATINGS
CYBN: Fundamental Ratings
CYBN
OUTLOOK RATING
1..100
2
VALUATION
overvalued / fair valued / undervalued
1..100
18
Undervalued
PROFIT vs RISK RATING
1..100
96
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
90
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CYBNRXRX
RSI
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 3 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 3 days ago
75%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 3 days ago
83%
MACD
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 3 days ago
78%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 3 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 3 days ago
86%
Advances
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 18 days ago
85%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 12 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 8 days ago
85%
Aroon
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 3 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
CYBN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BFINX17.87N/A
N/A
Baron FinTech Retail
LGRRX30.30N/A
N/A
Loomis Sayles Growth A
FMQSX15.38N/A
N/A
Franklin Mutual Quest R
MIRSX23.01N/A
N/A
Victory Integrity Small/Mid-Cap Value R6
COSTX13.07N/A
N/A
Columbia Overseas Core Institutional 2

CYBN and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYBN has been loosely correlated with ATAI. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if CYBN jumps, then ATAI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYBN
1D Price
Change %
CYBN100%
-2.98%
ATAI - CYBN
42%
Loosely correlated
-5.83%
RXRX - CYBN
33%
Loosely correlated
-5.12%
ABSI - CYBN
31%
Poorly correlated
+6.43%
EYPT - CYBN
31%
Poorly correlated
-6.32%
SPRC - CYBN
29%
Poorly correlated
+59.01%
More

RXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RXRX has been closely correlated with CRSP. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if RXRX jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RXRX
1D Price
Change %
RXRX100%
-5.02%
CRSP - RXRX
68%
Closely correlated
-1.21%
ABSI - RXRX
63%
Loosely correlated
+6.63%
BEAM - RXRX
61%
Loosely correlated
-2.08%
ABCL - RXRX
58%
Loosely correlated
-2.62%
NTLA - RXRX
53%
Loosely correlated
-6.42%
More